SK Capital Partners, a private investment firm with a focus on the specialty materials, chemicals and healthcare sectors, has completed a controlling strategic growth investment in Halo Pharmaceutical, a provider of outsourced development and manufacturing services.

Halo Pharmaceutical is a technology-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid, and liquid dosage forms, with a particular focus on controlled substances. Halo has commercial relationships with a number of major pharmaceutical companies and maintains facilities in both the United States and Canada.

Source: Halo Pharmaceutical